New
Clinuvel receives takeover offer from a notorious short seller
Clinuvel Pharmaceuticals, drug developer for skin diseases from Melbourne, has received an unsolicited $95 million takeover offer from a controversial biotech company Retrophin, soon after sudden passing of Clinuvel's long time director Jack Wood.
On behalf of VRF management, we offer our sincere condolences to Jack's wife and family. Jack Wood was a remarkable person with a vision, big heart and brilliant sense of humor. Clinuvel is awaiting clearance from the European drug regulator for the use of its drug Scenesse in the treatment of a rare skin disease Erythropoietic Protoporphyria and potentially, in vitiligo.
Once a notorious short seller with loud public pressure, Reptophin's CEO Martin Shkreli now aims at drugs for ultra-rare and dangerous conditions. Clinuvel has appointed an advisory firm in the defense against the hostile offer.
FAQOther Questions
- How can I cure vitiligo?
Right now, there is no universal "cure," but we have entered a new era of treatment. Today, managing vitiligo isn’t just about "hiding" it; it’s about sophisticated science that...
- Safety of clinical trials. Can my child leave it for any reason?
Pediatric vitiligo trials · Safety and choice Who watches your child, what may need to pause and what happens if your family changes its mind. Two studies discussed here are eva...
- Awareness Days Similar to World Vitiligo Day
World Vitiligo Day, celebrated annually on June 25 since 2012, is a significant event dedicated to raising awareness about vitiligo and supporting those affected by the conditio...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.